INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 141 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2016. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $10,380,000 | +31.0% | 150,000 | +35.6% | 1.62% | +19.9% |
| Q4 2023 | $7,921,673 | -32.4% | 110,607 | -50.8% | 1.35% | -36.8% |
| Q3 2023 | $11,720,250 | +207.6% | 225,000 | +219.7% | 2.14% | +185.4% |
| Q1 2023 | $3,810,590 | -16.4% | 70,371 | -82.4% | 0.75% | +29.9% |
| Q4 2018 | $4,556,000 | +5.0% | 400,000 | +100.0% | 0.58% | -14.8% |
| Q3 2018 | $4,340,000 | +11.8% | 200,000 | +100.0% | 0.68% | -39.2% |
| Q2 2016 | $3,882,000 | – | 100,000 | – | 1.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |